Literature DB >> 8749703

A study of symptomatic drug use in migraine without aura.

F Maggioni1, A De Boni, P Rossi, A Villacara, G Zanchin.   

Abstract

We assessed the attack drugs taken by 200 migraine without aura patients (International Headache Society criteria, 1988) between 1989 and 1991. A detailed pharmacological history regarding the acute attack therapy adopted up until our initial visit was gathered, including the type of drug used, dosage, administration route, the time of starting therapy, treatment efficacy, and the frequency and types of undesirable effects, all of which were subsequently compared with the guidelines (1993) of the Italian Society for the Study of Headache (SISC). The most commonly used are non steroidal anti-inflammatory drugs (NSAIDs). We observed a similar high frequency in the use of combinations, particularly prophyphenazone and barbituric acid. The pirazolones, such as noramidopyrine and prophyphenazone, are also widely used as single agents, even though they are not considered by the guidelines. Our study underlines the fact that current drug use differs in several respects from the guidelines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749703     DOI: 10.1007/bf02229323

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  5 in total

1.  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

Authors: 
Journal:  Cephalalgia       Date:  1988       Impact factor: 6.292

2.  Pharmacological treatment of primary headache: analysis of current practice from a drug utilization study.

Authors:  G Scarani; E Beghi; G Tognoni
Journal:  Headache       Date:  1987-06       Impact factor: 5.887

Review 3.  Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine.

Authors:  C Dahlöf
Journal:  Cephalalgia       Date:  1993-06       Impact factor: 6.292

Review 4.  Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials.

Authors:  P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1993-08       Impact factor: 6.292

Review 5.  Sumatriptan in the acute treatment of migraine.

Authors:  M J Tansey; A J Pilgrim; K Lloyd
Journal:  J Neurol Sci       Date:  1993-01       Impact factor: 3.181

  5 in total
  1 in total

1.  Two alphaherpesvirus latency-associated gene products influence calcitonin gene-related peptide levels in rat trigeminal neurons.

Authors:  Mohamed A Hamza; Dennis M Higgins; William T Ruyechan
Journal:  Neurobiol Dis       Date:  2006-12-20       Impact factor: 5.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.